Compare PCB & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | RZLT |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.1M | 420.8M |
| IPO Year | 2018 | 2011 |
| Metric | PCB | RZLT |
|---|---|---|
| Price | $27.73 | $5.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $25.50 | $9.67 |
| AVG Volume (30 Days) | 36.2K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 48.28 | 26.32 |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $2,899,000.00 | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $18.83 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $19.70 | $1.07 |
| 52 Week High | $30.84 | $11.46 |
| Indicator | PCB | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 61.57 |
| Support Level | $27.31 | $4.48 |
| Resistance Level | $29.04 | $5.36 |
| Average True Range (ATR) | 0.72 | 0.28 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 22.84 | 58.16 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.